Subject to Change. 

8:00 AM – 8:45 AM
Registration and Breakfast

8:45 AM – 9:00 AM
Welcome and Opening Remarks

9:00 AM – 11:00 AM | 2.0 CE
Overview of Oral Pathology, Part 1
Dr. Ross Kerr

— A.M. BREAK, 11:00 AM – 11:15 AM —

11:15 AM – 12:30 PM | 1.25 CE
Overview of Oral Pathology, Part 2
Dr. Ross Kerr

— LUNCH/NETWORKING BREAK, 12:35 PM – 1:15 PM —

1:15 PM – 3:00 PM | 1.75 CE
Comprehensive Oral Exam “It’s More Than Grasping The Tongue”
Susan Cotten, BSDH, RDH, OMT

— P.M. BREAK, 3:00 PM – 3:15 PM —

3:15 PM – 4:45 PM | 1.5 CE
Salivary Diagnostics Hands-on Lab
Featuring Viome testing kits
Dr. Bruce Lieberthal, Chief Innovation Officer at Henry Schein
with Guruduth Banavar, PhD, Chief Technology Officer and Head of Discovery AI at Viome Life Sciences, Inc.

4:45 PM – 5:00 PM
Closing Remarks
__________________________

Up to 6.5 Live CE Credits*

* State stipulations on live CE change occasionally. Check with your state for specific guidelines.

Susan Cotten, BSDH, RDH, OMT

Susan is CEO of Oral Cancer Consulting and developed the “Cotten Method”, an oral cancer screening method and dental office system. She speaks on oral cancer and holds hands-on oral cancer screening workshops for dental professionals who want to have more confidence in screening, reduce the risk of liability, and increase early detection. In her career, Susan has performed over 60 thousand oral cancer screenings. She is the Dental Lead for the Alliance for HPV Free Colorado, developing and delivering training on HPV, the HPV vaccine, and HPV oropharyngeal cancer. She is an RDH Advisory Board member at The Oral Cancer Foundation, a Director with Dental Codeology Consortium, instructor at National Network for Healthcare Hygienists, and a published author.

In 2020, Susan received the Ethyl Covington Award from the Colorado Dental Hygiene Association/CODHA. She is a 2018 recipient of the Sunstar RDH Award of Distinction and CODHA Outstanding Contribution Award. Susan founded MAD(Make A Difference) for Healthy Smiles as a 2010-2011 member of Donny Osmond’s Make a Difference program and received Volunteer of the Year from the Oral Cancer Foundation in 2011.

 

Bruce Lieberthal, DDS

Dr. Lieberthal serves as the Chief Innovation Officer for Henry Schein, Inc.  In this role, he is at the nexus of evaluating hundreds of cutting edge solutions and technologies, advising the many medical and dental business units of Henry Schein on important emerging trends and helping connect the company’s global sales, marketing and distribution capabilities with important new products that help its customers run better practices and deliver excellent patient care.

He has held various positions with Henry Schein, Inc., including Vice President of Emerging Technologies, Vice President of Product Management and Development and had oversight responsibility for Henry Schein Medical Systems (MicroMD) between 2011 and 2017, led the ConnectDental team, focused on the launch of Henry Schein’s digital dentistry business and currently leads Henry Schein One’s DDX business.

Bruce graduated SUNY Buffalo’s School of Dentistry in 1983 and practiced dentistry for 14 years between 1984 and 1997. Bruce also serves on the boards of The Forsyth Institute and the Harvard School of Dental Medicine.

 

A. Ross Kerr, DDS, MSD, FDS, RCPS

Dr. Kerr is a Clinical Professor in the Department of Oral and Maxillofacial Pathology, Radiology and Medicine at NYU College of Dentistry and in the Department of Otolaryngology at NYU Langone Health Center.

Dr. Kerr received his DDS from McGill University in Montreal, Canada, and his MSD and certificate in Oral Medicine at the University of Washington. He is a recipient of NYU’s distinguished teaching award. He is a past president of the American Academy of Oral Medicine, director of the American Board of Oral Medicine, steering committee member of the World Workshop on Oral Medicine, member of the executive committee of the European Association of Oral Medicine, and member of the Scientific Advisory Board for the Oral Cancer Foundation.

His research experience includes the evaluation of current and emerging technologies for the detection and diagnosis of oral cancer and oral potentially malignant disorders. He has contributed more than 100 publications to the dental and medical literature.

This is a full-day hands-on course taking place at the tranquil waterfront Hyatt Regency Jersey City on the Hudson facing the iconic Manhattan skyline.

Hyatt Regency Jersey City on the Hudson
Two Exchange Place
Jersey City, New Jersey 07302

View Hotel Parking & Transportation

Travel, transportation, accommodations and parking for this event are the registrant’s responsibility. For information on hotel accommodations, please contact ADHA Meetings & Conventions at [email protected].

Upon completion of the program, you will be able to:

1. Interpret current oral cancer statistics analyzing factors influencing oral cancer rates.
2. Recognize early signs and symptoms of oral cancer.
3. Develop a differential diagnosis for oral cancers based on clinical and radiographic information.
4. Identify contemporary treatment options for oral cavity and oropharyngeal cancers.
5. Appreciate prognosis considerations and factors influencing treatment outcomes.
6. Develop practical skills for conducting a comprehensive oral examination.
7. Recognize the importance of a thorough oral examination in early detection of oral cancers.
8. Explore the potential of salivary biomarkers in early diagnosis and monitoring.
9. Foster effective communication among healthcare professionals involved in oral cancer care.
10. Appreciate the value of interdisciplinary communication in the management of oral cancers.